Guggenheim downgraded Novo Nordisk (NVO) to Neutral from Buy.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVO:
- Eli Lilly jumps as results from weight-loss pill study rival competitor’s
- Leerink bullish on Eli Lilly after ‘picture-perfect’ Phase 3 oral GLP-1 results
- Positive Outlook for Novo Nordisk: Buy Rating Driven by Legislative Changes and Robust Sales Growth
- Eli Lilly Stock (LLY) Goes Supersized after New Oral Weight Loss Drug Impresses in Trials
- Novo Nordisk downgraded to Market Perform from Outperform at BMO Capital